Glycomimetic E-Selectin Antagonists for Inflammatory Disease
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for inflammatory diseases and cancers often involve excessive or undesirable selectin-mediated cell adhesion, leading to tissue damage and metastasis, highlighting the need for inhibitors of selectin-mediated functions.
Innovation Solution
Development of glycomimetic E-selectin antagonists, including their prodrugs and pharmaceutical compositions, to inhibit E-selectin mediated functions by binding to E-selectin ligands, thereby reducing unwanted cell adhesion and migration.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If selectin-mediated cell adhesion is enhanced to improve immune defense and fight infection, then leukocyte recruitment to infected tissue is improved, but tissue damage and abnormal cell adhesion occur resulting in harmful effects
Solution Approach 1:
The patent applies local quality by designing selectin antagonists with specific molecular structures (Formula I compounds featuring sialyl-Lewisx mimics) that selectively inhibit selectin-mediated adhesion in pathological contexts while preserving normal immune function. The antagonists are targeted to sites of abnormal cell adhesion rather than systemically blocking all selectin activity
Solution Approach 2:
The patent employs parameter changes by modifying the chemical structure of natural ligands (sialyl-Lewisx) to create glycomimetic antagonists with optimized binding affinity and selectivity. The compounds in Formula I are designed with specific sugar moieties and linkers that tune the interaction parameters with selectin receptors to achieve therapeutic inhibition without complete blockade
2Productivity
If E-selectin activity is increased to promote leukocyte binding to endothelial cells, then inflammatory response is enhanced, but excessive adhesion leads to undesirable outcomes including metastasis
Solution Approach 1:
The patent uses intermediary compounds (E-selectin antagonists of Formula I) that mediate between the conflicting needs of leukocyte recruitment and prevention of abnormal adhesion. These antagonists act as molecular mediators that selectively interfere with pathological selectin-ligand interactions while allowing physiological immune responses to proceed
Solution Approach 2:
The patent applies inversion by using compounds that mimic the natural ligand structure (sialyl-Lewisx) but function as antagonists rather than agonists. The Formula I compounds are structural analogs that invert the biological effect from promoting adhesion to blocking adhesion, thereby treating the harmful effects of excessive selectin activity
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The glycomimetic E-selectin antagonists effectively treat and prevent diseases by inhibiting E-selectin mediated functions, reducing tissue damage and metastasis, and can be used in conjunction with chemotherapy and radiotherapy to enhance hematopoietic stem cell survival and mobilization.
Implementation Method 1
inhibit E-selectin mediated functions by binding to E-selectin ligands
Data Source
AI summary
Compounds, compositions, and methods for treatment and/or prevention of at least one disease, disorder, and/or condition by inhibiting binding of an E-selectin to an E-selectin ligand are disclosed. For example, E-selectin antagonists are described and pharmaceutical compositions comprising at least one of the same.